SCHEMBL26175652

SCHEMBL26175652

CN1CCN(c2cc(-c3cnc4[nH]cc(-c5ccn6nccc6c5)c4c3)ccn2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 6/20 0.52
IL2 P60568 4/20 0.52
TNIK Q9UKE5 10/20 0.46
DYRK1A Q13627 2/20 0.44
CLK2 P49760 1/20 0.44
CLK3 P49761 1/20 0.44
MAP3K11 Q16584 4/20 0.43
SGK1 O00141 1/20 0.42
IKBKB O14920 1/20 0.42
AURKA O14965 1/20 0.42
CHUK O15111 1/20 0.42
PRKAB2 O43741 1/20 0.42
ROCK2 O75116 1/20 0.42
ABL1 P00519 1/20 0.42
NTRK1 P04629 1/20 0.42
INSR P06213 1/20 0.42
LCK P06239 1/20 0.42
CDK1 P06493 1/20 0.42
IGF1R P08069 1/20 0.42
MET P08581 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30400689 0.90 MAP4K1 (0.65) MAP4K1IL2TNIKMAP3K11SGK1
SCHEMBL26175613 0.90 MAP4K1 (0.65) MAP4K1IL2TNIKMAP3K11SGK1
SCHEMBL26175663 0.88 MAP4K1 (0.63) MAP4K1IL2TNIKDYRK1ACLK2
SCHEMBL30400428 0.87 DYRK1A (0.52) MAP4K1IL2TNIKDYRK1ACLK2
SCHEMBL26177429 0.87 DYRK1A (0.52) MAP4K1IL2TNIKDYRK1ACLK2
SCHEMBL26175649 0.86 MAP4K1 (0.51) MAP4K1IL2TNIKDYRK1ACLK2
SCHEMBL26174845 0.85 IL2 (0.51) MAP4K1IL2TNIKDYRK1AMAPK1
SCHEMBL26175268 0.85 TNIK (0.62) MAP4K1IL2TNIK
SCHEMBL30399953 0.83 IL2 (0.48) MAP4K1IL2TNIKDYRK1ALRRK2
SCHEMBL26175356 0.83 IL2 (0.57) MAP4K1IL2TNIKLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415817-A1 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 EP claimed
WO-2023064349-A1 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 WO claimed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 US disclosed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 MAP4K1 14/4885IL2 2765/4885TNIK 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.